Medication-related Problems in CKD

Advances in Chronic Kidney Disease

Volumn 17, Issue 5, 2010, Pages 404-412

  Cardone, Katie E ^a,b   Bacchus, Shaffeeulah ^c   Assimon, Magdalene M ^a,b   Pai, Amy Barton ^a,b   Manley, Harold J ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Village Health Disease Management   (United States)

^c VillageHealth Disease Management ^*  (United States)

Author keywords

Chronic kidney disease; Healthcare utilization; Medication related problems; Pharmacist

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIALYSIS; DIET RESTRICTION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG OVERDOSE; ELECTRONIC PRESCRIBING; EMPOWERMENT; EVIDENCE BASED PRACTICE; GOOD CLINICAL PRACTICE; HEALTH INSURANCE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; INSURANCE; MEDICAL RECORD; MEDICARE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PHARMACIST; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF MONITORING;

EID: 77955838680     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.06.004     Document Type: Review

References (48)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
2. United States Renal Data Systems (USRDS): 2009 Annual Data Report 2009, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD.
3. Patel H.R., Pruchnicki M.C., Hall L.E. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann Pharmacother 2005, 39:22-27.
4. Manley H.J., Garvin C.G., Drayer D.K., et al. Medication prescribing patterns in ambulatory hemodialysis patients: Comparisons of USRDS to a large non-for-profit dialysis provider. Nephrol Dial Transplant 2004, 19:1842-1848.
5. Ernst F.R., Grizzle A.J. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc 2001, 41:192-199.
6. Hepler C.D., Strand L.M. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990, 47:533-543.
7. Manley H.J., McClaran M.L., Overbay D.K., et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis 2003, 41:386-393.
8. Winterstein A.G., Sauer B.C., Hepler C.D., et al. Preventable drug-related hospital admissions. Ann Pharmacother 2002, 36:1238-1248.
9. Koecheler J.A., Abramowitz P.W., Swim S.E., et al. Indicators for the selection of ambulatory patients who warrant pharmacist monitoring. Am J Hosp Pharm 1989, 46:729-732.
10. Manley H.J., Cannella C.A. Nondialysis (home) medication utilization and cost in diabetic and nondiabetic hemodialysis patients. Nephrol News Issues 2005, 19. 27-28, 33-34, 36-38.
11. United States Renal Data Systems (USRDS): 2000 Annual Data Report 2000, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD.
12. Bleyer A.J., Hylander B., Sudo H., et al. An international study of patient compliance with hemodialysis. JAMA 1999, 281:1211-1213.
13. Long J.M., Kee C.C., Graham M.W., et al. Medication compliance and the older hemodialysis patient. ANNA J 1998, 25:43-49.
14. Curtin R.B., Svarstad B.L., Keller T.H. Hemodialysis patients' noncompliance with oral medications. ANNA J 1999, 26:307-316.
15. Bander S.J., Walters B.A. Hemodialysis morbidity and mortality: Links to patient non-compliance. Curr Opin Nephrol Hypertens 1998, 7:649-653.
16. Leggat J.E., Orzol S.M., Hulbert-Shearon T.E., et al. Noncompliance in hemodialysis: Predictors and survival analysis. Am J Kidney Dis 1998, 32:139-145.
17. Denhaerynck K., Manhaeve D., Dobbels F., et al. Prevalence and consequences of nonadherence to hemodialysis regimens. Am J Crit Care 2007, 16:222-235.
18. Manley H.J., Drayer D.K., McClaran M., et al. Drug record discrepancies in an outpatient electronic medical record: Frequency, type, and potential impact on patient care at a hemodialysis center. Pharmacotherapy 2003, 23:231-239.
19. Pai A.B., Boyd A., Depczynski J., et al. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: A 2-year, randomized, controlled study. Pharmacotherapy 2009, 29:1433-1440.
20. Hug B.L., Witkowski D.J., Sox C.M., et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney. Kidney Int 2009, 76:1192-1198.
21. Pai A.B., Boyd A., Chavez A., et al. Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: A 2-year randomized, controlled study. Hemodial Int 2009, 13:72-79.
22. Ong S.W., Fernandes O.A., Cesta A., et al. Drug-related problems on hospital admission: Relationship to medication information transfer. Ann Pharmacother 2006, 40:408-413.
23. Manley H.J., Cannella C.L., Bailie G.R., et al. Medication-related problems in ambulatory hemodialysis patients: A pooled analysis of published reports. Am J Kidney Dis 2005, 46:669-680.
24. Manley H.J., Drayer D.K., Muther R.S. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 2003, 4:10.
25. Possidente C.J., Bailie G.R., Hood V.L. Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health Syst Pharm 1999, 56:1961-1964.
26. Grabe D.W., Low C.L., Bailie G.R., et al. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997, 121:459-464.
27. Kaplan B., Shimp L.A., Mason N.A., et al. Chronic hemodialysis patients. Part II: Reducing drug-related problems through application of the focused drug therapy review program. Ann Pharm 1994, 28:320-324.
28. Kaplan B., Mason N.A., Shimp L.A., et al. Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharm 1994, 28:316-318.
29. Tang I., Vrahnos D., Hatoum H., et al. Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Therapeut 1993, 15:459-464.
30. Bailie G.R., Eisele G., Liu L., et al. Patterns of medication use in the RRI-CKD study: Focus on medications with cardiovascular effects. Nephrol Dial Transplant 2005, 20:1110-1115.
31. Nissenson A.R., Collins A.J., Hurley J., et al. Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns. J Am Soc Nephrol 2001, 12:1713-1720.
32. Kausz A.T., Khan S.S., Abichandani R., et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 2001, 12:1501-1507.
33. Tozawa M., Iseki K., Iseki C., et al. Analysis of drug prescription in chronic hemodialysis patients. Nephrol Dial Transplant 2002, 17:1819-1824.
34. Manley H.J., Carroll C. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial 2002, 15:45-49.
35. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009, 76:S113. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
36. Hirth R.A., Greer S.L., Albert J.M., Young E.W., Piette J.D. Out of pocket spending and medication adherence among dialysis patients in twelve countries. Health Affairs 2008, 27:89-103.
37. Kripalani S., Yao X., Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Arch Intern Med 2007, 167:540-550.
38. Holley J.L., Devore C.C. Why all prescribed medications are not taken: Results from a survey of chronic dialysis patients. Adv Perit Dial 2006, 22:162-166.
39. Patient Protection and Affordable Care Act. HR 4872-9, Section 1860D-42 of the Social Security Act (42 U.S.C. 1395w-152).
40. Doshi J.A., Zhu J., Lee B.Y., et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009, 119:390-397.
41. Miller W.R., Rollnick S. Motivational interviewing: Preparing people for change 2002, Guilford Press, New York, NY. 2nd ed.
42. Miller W.R., Rollnick S. What is MI?. Behav Cognit Psychother 1995, 23:325-334.
43. Mason N.A., Bakus J. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial 2009, 23:55-61.
44. Wang H.Y., Chan A.L., Chen M.T., et al. Effects of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics. Transplant Proc 2008, 40:2319-2323.
45. Chisholm M.A., Vollenweider L.J., Mulloy L.L., et al. Direct patient care services provided by a pharmacist on a multidisciplinary renal transplant team. Am J Health Syst Pharm 2000, 57:1994-1996.
46. Harchowal J.T. Drug-related problems on a renal unit. Br J Renal Med 1997, 2:22-24.
47. Manley H.J., Drayer D.K. Identification and resolution of cardiovascular medication-related problems in hemodialysis (HD) patients: A 3 year experience. J Am Soc Nephrol 2005, 16:472A.
48. Joy M.S., Matzke G.R. Nephrology pharmacy: Historical reflections and future challenges. Ann Pharmacother 2007, 41:1884-1886.